Navigation Links
ULURU Inc. Completes Redemption Of Preferred Stock
Date:8/19/2013

ADDISON, Texas, Aug. 19, 2013 /PRNewswire/ -- ULURU Inc. (OTCQB: ULUR), a specialty pharmaceutical company focused on the development of a portfolio of wound management and oral care products, today announced it has completed the redemption of all of the Company's outstanding preferred stock.

On August 15, 2013, the Company provided notice to Ironridge Global III, LLC for the redemption of all of the Company's Series A Preferred Stock held by Ironridge Global, a total of 65 Series A Preferred shares which, if elected, would have converted into 928,571 shares of common stock at a conversion price of $0.70 per share.  An affiliate of Ironridge Global III, LLC, the issuer of promissory notes held by the Company, due 7.5 years from the issue date, in the principal amount of $969,000, agreed to accept the cancellation of the promissory notes held by the Company in exchange for the redemption of the Series A Preferred shares.

Commenting on the redemption, Kerry P. Gray, President and CEO of ULURU, stated, "We are very pleased to have completed the redemption of all outstanding preferred stock without having to use any of our cash resources.  This transaction avoids the potential for the issuance of additional shares of common stock upon conversion and simplifies our capital structure." 

About ULURU Inc.:
ULURU Inc. is a specialty pharmaceutical company focused on the development of a portfolio of wound management and oral care products to provide patients and consumers improved clinical outcomes through controlled delivery utilizing its innovative Nanoflex® Aggregate technology and OraDisc™ transmucosal delivery system.  For further information about ULURU Inc., please visit our website at www.ULURUinc.com.  For further information about Altrazeal®, please visit www.Altrazeal.com.

This press release contains certain statements that are forward-looking within the meaning of Section 27a of the Securities Act of 1933, as amended.  These statements are subject to numerous risks and uncertainties, including but not limited to the benefits of redeeming the Company's preferred stock, the simplification of our capital structure due to the redemption, and the risk factors detailed in the Company's Annual Report on Form 10-K for the year ended December 31, 2012, and other reports filed by us with the Securities and Exchange Commission.

Contact: Company
Kerry P. Gray
President & CEO
Terry K. Wallberg
Vice President & CFO
(214) 905-5145


'/>"/>
SOURCE ULURU Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. ULURU Inc. Reports Second Quarter 2013 Financial Results
2. ULURU Inc. Announces Conference Call To Discuss Financial Results For The Second Quarter Ended June 30, 2013
3. ULURU Inc. Reports First Quarter 2013 Financial Results
4. ULURU Inc. Announces Conference Call To Discuss Financial Results For The First Quarter Ended March 31, 2013
5. ULURU Inc. Reports Financial Results For Fourth Quarter And Year Ending December 31, 2012
6. ULURU Inc. Announces Conference Call to Discuss Financial Results for the Fourth Quarter and Year Ended December 31, 2012 and to Provide a Business Update
7. ULURU Inc. Business Update And Outlook
8. ULURU Inc. Announces Closing Of $440,000 Private Placement
9. ULURU Inc. Reports Third Quarter 2012 Financial Results
10. ULURU Inc. Announces The First Shipment Of Veterinary Product
11. ULURU Inc. Announces First Order Of Altrazeal For European Launch
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/24/2017)... , January 24, 2017 For today, ... GENE ), Alder Biopharmaceuticals Inc. (NASDAQ: ... ), and Egalet Corp. (NASDAQ: EGLT ). These ... lower on Monday, January 23 rd , 2017, with the ... health care companies in the S&P 500 also were down ...
(Date:1/24/2017)... YORK , Jan. 23, 2017 Laboratory ... the global use of mass spectrometry in both clinical ... current ,MS analysis, global market size of $6.8 billion ... the next four years, profiles the use of mass ... encompassing 21 countries. This study investigated growth in the ...
(Date:1/24/2017)... , January 23, 2017 ArisGlobal, ... life sciences, announces agClinical 3.3, the latest version of ... enables life science organizations to confidently and efficiently meet ... better manage the electronic trial master file so that ... ...
Breaking Medicine Technology:
(Date:1/24/2017)... ... January 24, 2017 , ... ... during the Annual Enrollment Period (AEP) and the Open Enrollment Period (OEP). 2016 ... insurance coverage. Mainly, people are witnessing higher deductibles, rising premiums, and few choices ...
(Date:1/24/2017)... , ... January 24, 2017 , ... ... newest technology offering, Processing Assurance Control Equipment (PACE), at the International Production and ... , PeroxyChem’s booth will highlight the new technology that is used in poultry ...
(Date:1/24/2017)... (PRWEB) , ... January 24, 2017 , ... ... product “Lacto-Freedom” was recently accepted as a Registered Trademark by the United States ... from using a similar name which could confuse consumers into thinking that other ...
(Date:1/24/2017)... , ... January 24, 2017 , ... Learn to use ... athletics or even in relationships. Course offered by Dr. Carol Francis at PVNET ... to limited seating and the many hands-on experiences. , Dr. Carol Francis ...
(Date:1/24/2017)... ... January 24, 2017 , ... Seceon , the only ... real-time, today announced a strategic partnership with Paramount , the Middle East’s ... protect their critical information assets and infrastructure, in a comprehensive and cost effective ...
Breaking Medicine News(10 mins):